Texas Biotechnology and SmithKline
Selected Abstract
Texas Biotechnology and SmithKline Beecham File Supplemental New Drug Application of Argatroban for HIT Patients Undergoing Percutaneous Coronary Interventions.
HOUSTON, Dec. 21 /PRNewswire/ -- Texas Biotechnology Corporation (Amex: TXB) and SmithKline Beecham (NYSE: SBH) stated that a supplemental New Drug Application (sNDA) for Argatroban has been filed with the U.S. Food & Drug Administration. The sNDA, if approved, would expand the use of ... December 21, 2000; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Texas Biotechnology and SmithKline Beecham File Supplemental New Drug Application of Argatroban for HIT Patients Undergoing Percutaneous Coronary Interventions.
2.
Texas Biotechnology and SmithKline Beecham Form Alliance to Market and Develop NOVASTAN(R) (argatroban) in North America
3.
Texas Biotechnology's NOVASTAN(R) NDA Granted Priority Review Status by the FDA
|
